(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

The pharmaceutical company Amgen announced Wednesday that it will decrease the price of its cholesterol lowering drug Repatha by 60%. The company said some patients weren't filling their prescriptions ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

To view the multimedia assets associated with this press release, please click: http://www.multivu.com/players/English/7414052-amgen-repatha/. The EC approved Repatha ...

As copycats eat into Amgen’s older products, the big biotech is looking to its newer launches to stem the tide. But some of them are not getting it done. JPMorgan analyst Cory Kasimov name-dropped ...

Amgen cut the price of its cholesterol drug Repatha by 60%. The drug used to have a list price of more than $14,000 a year. Now, it'll be $5,850 a year. The goal is to make the drug more affordable to ...

(Reuters) - Amgen Inc , looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.

Amgen is cutting the list price of its cholesterol drug Repatha by 60% to $5,850 in an unprecedented move to make the drug available to senior citizens. “We’ve got to make sure those who need [Repatha ...